Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 21 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Anakinra for Still’s disease	Anakinra (Kineret)	Juvenile idiopathic arthritis	Rheumatology	2018	View \| Download
Baricitinib for treating juvenile idiopathic arthritis in paediatric patients	Baricitinib (LY3009104; Olumiant)	Juvenile psoriatic arthritis	Rheumatology	2022	View \| Download
Bimekizumab for active psoriatic arthritis	Bimekizumab (UCB4940)	Psoriatic arthritis	Dermatology , Rheumatology	2021	View \| Download
Bimekizumab for non-radiographic axial spondyloarthritis	Bimekizumab (UCB4940)	Axial spondyloarthritis	Rheumatology	2021	View \| Download
Deucravacitinib for treating active psoriatic arthritis	Deucravacitinib (BMS-986165)	Psoriatic arthritis	Dermatology , Rheumatology	2023	View \| Download
Filgotinib for moderate to severe active rheumatoid arthritis	Filgotinib (GLPG-0634; filgotinib maleate) , Methotrexate (MTX; Otrexup; Vibex MTX; MQX-5902; methotrexate disodium; methotrexate sodium) , other nonbiologic DMARDs	Rheumatoid arthritis	Rheumatology	2019	View \| Download
Guselkumab for active psoriatic arthritis	Guselkumab (Tremfya; CNTO-1959)	Psoriatic arthritis	Dermatology , Rheumatology	2019	View \| Download
Ixekizumab for axial spondyloarthritis	Ixekizumab (Taltz; LY2439821)	Spondyloarthritis	Musculoskeletal System , Rheumatology	2018	View \| Download
Otilimab in combination with conventional synthetic DMARDs for treating rheumatoid arthritis	Otilimab	Rheumatoid arthritis	Rheumatology	2022	View \| Download
Risankizumab (by subcutaneous injection) for Active Psoriatic Arthritis After Inadequate Control or Intolerance to Conventional Drugs	Risankizumab (BI 655066; Skyrizi; ABBV 066)	Psoriatic arthritis	Dermatology , Rheumatology	2017	View \| Download